

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
FERČEJ TEMELJOTOV, Darja)	Group Art Unit: 1611
Application No.: 09/913,752)	Examiner: Landau, Sharmila G.
Filed: November 21, 2001)	Confirmation No.: 5309
)	
For: Directly Compressible Matrix for)	
Controlled Release of Single Daily Doses)	
of Clarithromycin)	
)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUBMISSION UNDER 37 C.F.R. 3.73(b)

Assignor, LEK, Tovarna Farmaceutskih in Kemičnih Izdelkov, D.D., duly organized under the laws of Slovenia and having its principal place of business at Verovškova 57, 1526 Ljubljana, Slovenia, represents that it is the assignor of the entire right, title and interest in and to the above-identified application, Application No. 09/913,752, filed November 21, 2001, for Directly Compressible Matrix for Controlled Release of Single Daily Doses of Clarithromycin, in the names of Darja FERČEJ TEMELJOTOV, Milojka MOHAR, Mateja SALOBIR, Ljubomira Barbara REBIČ and Marko OPRESNIK, as indicated by the true and correct copy of the original assignment attached hereto

The undersigned is authorized to act on behalf of assignor.

Respectfully submitted,

By: 

Name: Alenka KOSAK

Title: Director IP Projects & Trademarks

Assignor: LEK, Tovarna
Farmaceutskih in Kemisnih
Izdelkov, D.D.

Dated: 18.03.2008

Assignment

In consideration of One Dollar (\$1.00), and other good and valuable consideration, the receipt of which is hereby acknowledged, We, the undersigned,

Darja FERČEJ TEMELJOVIČ, Milojka MOHAR, Mateja SALOBIR, Ljubomira Barbara REBIČ, and Marko OPRESNIK

Hereby sell, assign and transfer to

LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d.

a corporation of Slovenia
having a place of business at Verovškova 57, 1526 Ljubljana, Slovenia
its successors, assigns and legal representatives, the entire right, title and interest for the United States and all foreign countries, in and to any and all improvements which are disclosed in the application for United States Letters Patent, which
is entitled DIRECTLY COMPRESSIBLE MATRIX FOR CONTROLLED RELEASE OF SINGLE DAILY DOSES
OF CLARITHROMYCIN

, and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other applications for Letters Patent which have been or shall be filed in the United States and all foreign countries on any of said improvements; and in and to all original and reissued patents which have been or shall be issued in the United States and all foreign countries on said improvements;

Agree that said Assignee may apply for and receive Letters Patent for said improvements in its own name; and that, when requested, without charge to but at the expense of said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all said improvements; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns, and representatives, all facts known to the undersigned relating to said improvements and the history thereof; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements and all applications for patents and all patents on said improvements, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

August 27, 2001

Darja Ferčej (L.S.)

August 27, 2001

Milica Mohar (L.S.)

August 27, 2001

August 27, 2001

August 24, 2001

Marko Opresnik